Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Current Taxes (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Current Taxes for 3 consecutive years, with $2.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Taxes fell 6.9% to $2.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.6 million, a 6.9% decrease, with the full-year FY2024 number at $2.8 million, down 43.98% from a year prior.
  • Current Taxes was $2.6 million for Q3 2025 at Gyre Therapeutics, up from $1.1 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $6.5 million in Q1 2024 to a low of $569000.0 in Q1 2025.
  • A 3-year average of $3.0 million and a median of $2.7 million in 2024 define the central range for Current Taxes.
  • Biggest YoY gain for Current Taxes was 6.9% in 2025; the steepest drop was 91.21% in 2025.
  • Gyre Therapeutics' Current Taxes stood at $5.1 million in 2023, then plummeted by 43.98% to $2.8 million in 2024, then fell by 6.53% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Current Taxes are $2.6 million (Q3 2025), $1.1 million (Q2 2025), and $569000.0 (Q1 2025).